share_log

EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25

Benzinga Real-time News ·  Jan 5, 2023 04:45

EF Hutton analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:ATRA) with a Buy rating and announces Price Target of $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment